Results 61 to 70 of about 10,072 (202)

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab

Therapeutics and Clinical Risk Management, 2015
Arpita Shah Department of Pharmacy, Georgia Regents University Medical Center, Augusta, GA, USA Abstract: Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with a higher affinity for CD20 epitope, enhanced antibody-dependent
Shah A
doaj  

Trends in the Dispensing of Oral Anti‐Cancer Medications Across Australia Over 10 Years

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 4, April 2025.
ABSTRACT Purpose Oral anti‐cancer medications (OAMs) are easily administered yet high‐risk treatments. Few studies have investigated national and subnational trends in OAM dispensing. We aimed to examine 10‐year trends in Australia's OAM dispensing at the national level as well as by state/territory and medication type/class.
Michael James Leach, Emily Griffin, Sinead Hickmott, Holly Atkinson, Louise Bettiol, Eli Ristevski   +5 more
wiley   +1 more source

Retrospective Analysis of Clinical Presentation, Prognostic Factors and Outcome in 32 Dogs with Subcutaneous Mast Cell Tumours Treated with a Curative‐Intent Approach

Veterinary Medicine and Science, Volume 11, Issue 2, March 2025.
Subcutaneous mast cell tumours (ScMCTs) have been traditionally associated with a good prognosis, with low rates of recurrence and metastasis. This study aims to describe the clinical presentation, outcome, and prognostic factors in dogs diagnosed with ScMCTs and treated with a curative‐intent approach. Our results suggest that despite the overall good
Xavier Escoda Llorens, Eduard Anadon Cámara, Núria Llorens Bárbara, Ignacio Rodríguez‐Pizá   +3 more
wiley   +1 more source

Wound, pressure ulcer, and burn guidelines (2023)―4: Guidelines for the management of connective tissue disease/vasculitis‐associated skin ulcers, third edition

The Journal of Dermatology, EarlyView.
Yoshihide Asano, Jun Asai, Takayuki Ishii, Yohei Iwata, Masanari Kodera, Chie Miyabe, Akihiko Uchiyama, Youichi Ogawa, Ken Okamura, Mari Kishibe, Yuta Koike, Yorihisa Kotobuki, Noriki Fujimoto, Takuya Miyagi, Yukie Yamaguchi, Ayumi Yoshizaki, Reiko Omori, Takeshi Nakanishi, Hiroshi Fujiwara, Takeo Maekawa, Sei‐ichiro Motegi, Yuichiro Yoshino, Minoru Hasegawa, Manabu Fujimoto, Takao Tachibana, Wound, Pressure Ulcer, and Burn Guidelines Drafting Committee (connective tissue disease/vasculitis group)   +27 more
wiley   +1 more source

Treatment outcomes of dogs with transitional cell carcinoma

Frontiers in Veterinary Science
Transitional cell carcinoma (TCC) is the most prevalent cancer of the urinary tract in dogs. The prognosis is often poor, and the optimal standard treatment has not been established. The objectives of this study were to (1) describe the clinical outcomes
Ka To Chu, Omid Nekouei, Antonio Giuliano, Antonio Giuliano   +3 more
doaj   +1 more source

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

Haematologica, 2018
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic leukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with ...
Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Osnat Bairey, Nancy L. Bartlett, Jan A. Burger, Peter Hillmen, Steven Coutre, Stephen Devereux, Sebastian Grosicki, Helen McCarthy, Jianyong Li, David Simpson, Fritz Offner, Carol Moreno, Cathy Zhou, Lori Styles, Danelle James, Thomas J. Kipps, Paolo Ghia   +20 more
doaj   +1 more source

Efficacy of combination of rituximab therapy with chlorambucil plus prednisolone (R-LP) Protocol as treatment line in chronic lymphocytic leukemia patients

Iraqi Journal of Hematology, 2015
Background: Chronic lymphocytic leukemia (CLL) remains an incurable disease with variable course. It is typically responsive to several courses of chemotherapy.
Waseem F Al Tameemi
doaj  

Combination of Chlorambucil and Mercaptopurine Show Effective Anti-Cancer Effects in Mice Model

International Journal of Nanomedicine, 2023
Weibing Xu,1 Yuxin Di,1 Shengjing Chu,1 Zixuan Wang,1 Haitao Long,1 Lumei Pu,1 Runtian Ma,1 Yanwei Wang2 1College of Science, Gansu Agricultural University, Lanzhou, 730000, People’s Republic of China; 2Department of Chemical and Materials Engineering ...
Xu W, Di Y, Chu S, Wang Z, Long H, Pu L, Ma R, Wang Y   +7 more
doaj  

Some effects of chlorambucil on enzymes of glutathione metabolism in drug-sensitive and -resistant strains of the Yoshida ascites sarcoma [PDF]

, 1969
Kenneth R. Harrap, Robert Jackson, Bridget T. Hill   +2 more
openalex   +1 more source

Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia [PDF]

, 1977
A Sawitsky, KR Rai, O Glidewell, RT Silver   +3 more
openalex   +1 more source